profit from every R$100 of sales.
R$0R$100
Hypera
R$22.47+1.17% today
+2.4% in 1 year
1-year low R$20.101-year high R$27.32
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay R$13.23 for every R$1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Hypera sold, what it kept, and what it did with the cash.
Sales went from R$7.55 billion in 2022 to R$7.70 billion in 2025, with R$1.20 billion of profit last year.
SalesProfit
Hypera handed back 37% of the cash it generated last year.
R$628M
Free cash flow 2025R$1.8B
Bought back its own sharesR$23M
Paid as dividendsR$628M
Cash vs. debtR$1.6B vs. R$9.3B
Hypera vs. similar companies
Hypera grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from R$100 of sales | Sales growth a year | Price per R$1 of profit |
|---|---|---|---|
| Hypera | 13.2× · Cheap | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Hypera's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of BRL | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 7,546 | 7,915 | 7,442 | 7,699 | |
| 4,762 | 4,996 | 4,381 | 4,546 | |
| 2,459 | 2,498 | 1,796 | 1,738 | |
| 2,766 | 2,877 | 2,230 | 2,261 | |
| 1,697 | 1,648 | 1,341 | 1,195 | |
| 2.63 | 2.56 | 2.06 | 1.87 | |
| 63.1% | 63.1% | 58.9% | 59.0% | |
| 32.6% | 31.6% | 24.1% | 22.6% | |
| 22.5% | 20.8% | 18.0% | 15.5% |
Balance sheet
| In millions of BRL | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 23,756 | 24,509 | 24,559 | 25,158 |
| Cash | 2,862 | 2,581 | 1,739 | 1,646 |
| Total debt | 9,681 | 9,962 | 9,397 | 9,337 |
| Total liabilities | 13,100 | 12,991 | 12,457 | 12,634 |
| 10,646 | 11,504 | 12,096 | 12,522 | |
| 646 | 644 | 651 | 636 | |
| 8.4% | 8.1% | 6.0% | 5.9% | |
| 15.9% | 14.3% | 11.1% | 9.5% |
Cash flow
| In millions of BRL | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,039 | 2,396 | 2,540 | 2,574 | |
| 1,509 | 813 | 772 | 799 | |
| 529 | 1,583 | 1,767 | 1,775 | |
| Dividends paid | 806 | 760 | 787 | 628 |
| 87 | 88 | 56 | 23 | |
| 25 | 46 | 33 | 23 |
Valuation
- 13.2×
- –
- –
- 1.2×
- 2.1×
- 8.9×
- 10.4×
- 11.2%
- 7.6%
- 4.0%
Profitability
- 59.0%
- 22.6%
- 15.5%
- –
- 5.9%
- 7.1%
- –
- –
- –
- –
Growth
- +0.7%
- −10.7%
- –
- –
- −0.5%
Financial health
- 3.4×
- 0.75
- –
- 1.9×
- 1.47
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 47%of 946
Top 19%of 872
Top 16%of 563
Bottom 17%of 868
Top 5%of 986
4.0%of the share price, paid each year
On $1,000 invested$40a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
52.5% of its profit
Room to growStretchedMore than it earns: 35.4%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
59No pass
Benjamin Graham
75Pass
Philip Fisher
51No pass
Peter Lynch
25No pass
Joel Greenblatt
39No pass
Charlie Munger
47No pass
Terry Smith
45No pass
Questions about Hypera
Is Hypera a good stock to buy?
A business with weak numbers, and the price looks low. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Hypera AI analysis
What does Hypera do?
Hypera S.A. operates as a pharmaceutical company in Brazil. It is in Drug Manufacturers - Specialty & Generic, based in São Paulo, SP, Brazil, with 10,564 employees.
Does Hypera pay a dividend?
Yes. At today's price the dividend is 4.0% a year, about 53% of its yearly profit. In 2025 it paid out R$628 million in dividends.
Is Hypera stock halal?
No. Hypera does not pass our halal screen: its debt is 59% of its market value, at or above the 33% limit. How we check
How has Hypera stock done over the past year?
Up 2.4% over the past twelve months, to R$22.47. It traded between R$20.10 and R$27.32 and is 17.8% below its high.
Who are Hypera's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Hypera's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.